Long-Acting Antibody Treatment for HIV/AIDS Patients with Jimmy Chang TaiMed Biologics TRANSCRIPT

Jimmy Chang, Chairman and CEO of TaiMed Biologics,  is approaching critical unmet needs in HIV care, particularly for aging patients with comorbidities who face risks from drug-drug interactions with multiple medications. The company is advancing the next-generation antibodies designed for bimonthly injections and an alternative to daily oral medications, while minimizing enzymatic metabolism and associated drug interactions. While successful treatments for HIV have shifted the focus from survival to quality of life and managing a chronic condition, new challenges have emerged to ensure patient convenience and adherence. 

Jimmy explains, "TaiMed is a biotech company based in Taiwan. Our focus is to develop innovative product for the HIV. And actually, over the years we have developed the first CD4-directed antibody for HIV treatment, and the product was approved in the US. And today we are currently focusing on developing the CD4-targeting antibody in a combination for long-acting HIV treatment."  

"So in today's world, HIV therapies, HIV patients, or the people living with HIV, the field is HIV as a chronic disease. The patient can live longer and healthier just like everybody else. However, it requires dedication and commitment to medication because there's no cure today. HIV, the virus keeps mutating. So if the disease is not under control, this could be problematic, and basically one day the patient may run into a situation where most of the drugs do not work for the patient."

"So in the earlier days, the innovations or the medications were mainly trying to have the virus under control, with the focus of the medications. And so nowadays, because people living with HIV actually have a very good health condition, just like typical individuals live longer and healthier. So this comorbidity, or we call it the polypharmacy drug-drug interaction, is really the challenge that the physicians or patients have to face every day. And with our innovations, we believe we have the opportunity to offer another innovative medication to specifically address those challenges."

#TaiMed #HIVCare #LongActingTherapies #AntibodyTherapeutics #CD4 #Polypharmacy #InfectiousDiseases #TaiMedBiologics #EmpoweredPatient #HealthcareInnovation

taimedbiologics.com

Listen to the podcast here